TY - JOUR
T1 - A colostomy for large bowel obstruction at the end of life
T2 - What do patients gain from palliative surgery?
AU - Wilke, Roni Nitecki
AU - Iniesta, Maria D.
AU - Fellman, Bryan
AU - Jazaeri, Amir A.
AU - Meyer, Larissa A.
AU - Fleming, Nicole D.
AU - Schmeler, Kathleen M.
AU - Taylor, Jolyn S.
N1 - Publisher Copyright:
© 2024
PY - 2024/9
Y1 - 2024/9
N2 - Objectives: Malignant large bowel obstruction (LBO) is a frequent complication affecting women with gynecologic cancers and is an indication for emergent surgery. However, the life expectancy and subsequent medical care utilization are unknown. We sought to estimate overall survival (OS) following colostomy and describe subsequent healthcare utilization among patients with advanced gynecologic malignancies. Methods: We conducted a retrospective analysis of patients with advanced gynecologic cancers who underwent colostomy with palliative intent due to LBO at our institution between March 2014 and January 2023. Summary statistics were used to describe the clinical and demographic characteristics of the study population. OS was estimated using the Kaplan-Meier method, and we defined healthcare utilization at the end-of-life using criteria published by the National Quality Forum. Results: A total of 78 patients were included. The median age at the time of surgery was 61 (range: 34–83), and most patients had recurrent ovarian, fallopian tube, or primary peritoneal cancer (n = 51, 65.4%), followed by cervical cancer (n = 16, 20.5%), and uterine cancer (n = 10, 12.8%). The median Charlson comorbidity index was 3 and median postoperative length of stay was five days (range: 1–26). The median follow-up for all patients was 4.5 months (range: 0.07–46.2), and the median OS was 4.5 months (95% CI: 2.9–6.0), including 12 patients (15.4%) with <30-day OS and 21 (26.9%) with <60-day OS. In the last 30 days of life, 62.7% of patients were re-admitted to the hospital, 53.0% were seen in the emergency department, and 18.5% were admitted to an intensive care unit. Conclusions: A significant proportion of patients died within 60 days of surgery, and many had high healthcare utilization at the end of life.
AB - Objectives: Malignant large bowel obstruction (LBO) is a frequent complication affecting women with gynecologic cancers and is an indication for emergent surgery. However, the life expectancy and subsequent medical care utilization are unknown. We sought to estimate overall survival (OS) following colostomy and describe subsequent healthcare utilization among patients with advanced gynecologic malignancies. Methods: We conducted a retrospective analysis of patients with advanced gynecologic cancers who underwent colostomy with palliative intent due to LBO at our institution between March 2014 and January 2023. Summary statistics were used to describe the clinical and demographic characteristics of the study population. OS was estimated using the Kaplan-Meier method, and we defined healthcare utilization at the end-of-life using criteria published by the National Quality Forum. Results: A total of 78 patients were included. The median age at the time of surgery was 61 (range: 34–83), and most patients had recurrent ovarian, fallopian tube, or primary peritoneal cancer (n = 51, 65.4%), followed by cervical cancer (n = 16, 20.5%), and uterine cancer (n = 10, 12.8%). The median Charlson comorbidity index was 3 and median postoperative length of stay was five days (range: 1–26). The median follow-up for all patients was 4.5 months (range: 0.07–46.2), and the median OS was 4.5 months (95% CI: 2.9–6.0), including 12 patients (15.4%) with <30-day OS and 21 (26.9%) with <60-day OS. In the last 30 days of life, 62.7% of patients were re-admitted to the hospital, 53.0% were seen in the emergency department, and 18.5% were admitted to an intensive care unit. Conclusions: A significant proportion of patients died within 60 days of surgery, and many had high healthcare utilization at the end of life.
KW - Colostomy
KW - End-of-life
KW - Gynecologic cancer
KW - Palliative care
UR - http://www.scopus.com/inward/record.url?scp=85197482052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85197482052&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2024.06.023
DO - 10.1016/j.ygyno.2024.06.023
M3 - Article
C2 - 38945019
AN - SCOPUS:85197482052
SN - 0090-8258
VL - 188
SP - 120
EP - 124
JO - Gynecologic oncology
JF - Gynecologic oncology
ER -